Amgen: We Expect To Double Biosimilar Sales By 2030
Interchangeability ‘Not Essential’ But A Differentiator; Ustekinumab Studies Continue
Executive Summary
Amgen management paid close attention to the company’s biosimilar portfolio and pipeline during several recent calls with investors, including what differentiates the firm from its rivals in the biosimilars space.
You may also be interested in...
Amgen’s Biosimilars Business Dips As Key Contributors Face Fresh Competition
Two of Amgen’s flagship biosimilar products saw a notable drop in sales in Q1 in the face of increased competition, but impending launches are expected to put the unit back on track.
Amgen Provides Ambitious Update On Biosimilars Business
Amgen CEO Robert Bradway has delivered confident predictions for the company’s biosimilars business at the J.P. Morgan Healthcare Conference, with a steady flow of launches expected to give the company’s earnings a significant boost over the coming years.
Teva: Amgen’s Interchangeable Humira Biosimilar Too Late For January 2023
Teva discussed its proposed rivals in the US biosimilar adalimumab space, biosimilar business development plans and prioritizing debt during its Q3 earnings call. The Israeli firm’s revenues succumbed to challenges in the US generics space.